SingHealth Polyclinics, Singapore, Singapore, Republic of Singapore.
Duke-NUS Medical School, Singapore, Republic of Singapore.
J Gen Intern Med. 2021 Jun;36(6):1514-1524. doi: 10.1007/s11606-021-06701-z. Epub 2021 Mar 26.
Coronary artery disease (CAD) risk prediction tools are useful decision supports. Their clinical impact has not been evaluated amongst Asians in primary care.
We aimed to develop and validate a diagnostic prediction model for CAD in Southeast Asians by comparing it against three existing tools.
We prospectively recruited patients presenting to primary care for chest pain between July 2013 and December 2016. CAD was diagnosed at tertiary institution and adjudicated. A logistic regression model was built, with validation by resampling. We validated the Duke Clinical Score (DCS), CAD Consortium Score (CCS), and Marburg Heart Score (MHS).
Discrimination and calibration quantify model performance, while net reclassification improvement and net benefit provide clinical insights.
CAD prevalence was 9.5% (158 of 1658 patients). Our model included age, gender, type 2 diabetes mellitus, hypertension, smoking, chest pain type, neck radiation, Q waves, and ST-T changes. The C-statistic was 0.808 (95% CI 0.776-0.840) and 0.815 (95% CI 0.782-0.847), for model without and with ECG respectively. C-statistics for DCS, CCS-basic, CCS-clinical, and MHS were 0.795 (95% CI 0.759-0.831), 0.756 (95% CI 0.717-0.794), 0.787 (95% CI 0.752-0.823), and 0.661 (95% CI 0.621-0.701). Our model (with ECG) correctly reclassified 100% of patients when compared with DCS and CCS-clinical respectively. At 5% threshold probability, the net benefit for our model (with ECG) was 0.063. The net benefit for DCS, CCS-basic, and CCS-clinical was 0.056, 0.060, and 0.065.
PRECISE (Predictive Risk scorE for CAD In Southeast Asians with chEst pain) performs well and demonstrates utility as a clinical decision support for diagnosing CAD among Southeast Asians.
冠心病(CAD)风险预测工具是有用的决策支持。它们在初级保健中的亚洲人群中的临床影响尚未得到评估。
通过与三种现有工具进行比较,我们旨在为东南亚人开发和验证 CAD 的诊断预测模型。
我们前瞻性地招募了 2013 年 7 月至 2016 年 12 月期间因胸痛就诊于初级保健的患者。在三级机构诊断 CAD 并进行裁决。建立了逻辑回归模型,并通过重采样进行验证。我们验证了 Duke 临床评分(DCS)、CAD 联合会评分(CCS)和 Marburg 心脏评分(MHS)。
区分度和校准度量化了模型性能,而净重新分类改善和净效益提供了临床见解。
CAD 的患病率为 9.5%(158/1658 例患者)。我们的模型包括年龄、性别、2 型糖尿病、高血压、吸烟、胸痛类型、颈部辐射、Q 波和 ST-T 改变。无心电图和有心电图时模型的 C 统计量分别为 0.808(95%CI 0.776-0.840)和 0.815(95%CI 0.782-0.847)。DCS、CCS-basic、CCS-clinical 和 MHS 的 C 统计量分别为 0.795(95%CI 0.759-0.831)、0.756(95%CI 0.717-0.794)、0.787(95%CI 0.752-0.823)和 0.661(95%CI 0.621-0.701)。与 DCS 和 CCS-clinical 相比,我们的模型(带心电图)正确地重新分类了 100%的患者。在 5%概率阈值下,我们的模型(带心电图)的净效益为 0.063。DCS、CCS-basic 和 CCS-clinical 的净效益分别为 0.056、0.060 和 0.065。
PRECISE(东南亚胸痛患者 CAD 预测风险评分)表现良好,并可作为东南亚人诊断 CAD 的临床决策支持工具。